Galmed Pharmaceuticals (GLMD) to Release Quarterly Earnings on Wednesday

Galmed Pharmaceuticals (NASDAQ:GLMD) will announce its earnings results before the market opens on Wednesday, May 9th. Analysts expect the company to announce earnings of ($0.20) per share for the quarter.

Galmed Pharmaceuticals (NASDAQ:GLMD) last issued its earnings results on Tuesday, March 13th. The biopharmaceutical company reported ($0.27) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.23) by ($0.04). The company had revenue of $0.27 million during the quarter, compared to analysts’ expectations of $0.28 million. Galmed Pharmaceuticals had a negative net margin of 1,133.55% and a negative return on equity of 133.50%. On average, analysts expect Galmed Pharmaceuticals to post $-1 EPS for the current fiscal year and $0 EPS for the next fiscal year.

Shares of NASDAQ:GLMD opened at $5.93 on Monday. The firm has a market capitalization of $91.53, a price-to-earnings ratio of -6.05 and a beta of 2.72. Galmed Pharmaceuticals has a 52-week low of $3.61 and a 52-week high of $12.22.

Several analysts have issued reports on GLMD shares. Maxim Group upgraded Galmed Pharmaceuticals from a “hold” rating to a “buy” rating and set a $14.00 target price for the company in a report on Thursday, March 15th. HC Wainwright upped their target price on Galmed Pharmaceuticals from $18.00 to $24.00 and gave the company a “buy” rating in a report on Monday, February 12th. ValuEngine cut Galmed Pharmaceuticals from a “hold” rating to a “sell” rating in a report on Wednesday, February 14th. Finally, Zacks Investment Research upgraded Galmed Pharmaceuticals from a “hold” rating to a “buy” rating and set a $13.00 price target for the company in a report on Wednesday, January 10th. Two investment analysts have rated the stock with a hold rating and four have issued a buy rating to the company. Galmed Pharmaceuticals currently has an average rating of “Buy” and an average price target of $20.40.

About Galmed Pharmaceuticals

Galmed Pharmaceuticals Ltd., a clinical-stage biopharmaceutical company, focuses on the development of therapeutics for the treatment of liver diseases. The company is develops Aramchol, an oral therapy, which is in ARREST study, a Phase IIb clinical study for the treatment of patients with overweight or obesity, and who are pre-diabetic or type-II-diabetic with non-alcoholic steato-hepatitis.

Earnings History for Galmed Pharmaceuticals (NASDAQ:GLMD)

Receive News & Ratings for Galmed Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Galmed Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

AurumCoin  Price Tops $11.52 on Major Exchanges
AurumCoin Price Tops $11.52 on Major Exchanges
Bitcoin Green 1-Day Volume Hits $145,178.00
Bitcoin Green 1-Day Volume Hits $145,178.00
$0.27 Earnings Per Share Expected for Shaw Communications  This Quarter
$0.27 Earnings Per Share Expected for Shaw Communications This Quarter
Nuveen New York Dividend Advan  Receives Daily Coverage Optimism Rating of 0.11
Nuveen New York Dividend Advan Receives Daily Coverage Optimism Rating of 0.11
Nuveen Tax Advantaged Total Re  Getting Somewhat Favorable Press Coverage, Analysis Shows
Nuveen Tax Advantaged Total Re Getting Somewhat Favorable Press Coverage, Analysis Shows
Brokerages Expect Daseke Inc.  Will Announce Earnings of $0.03 Per Share
Brokerages Expect Daseke Inc. Will Announce Earnings of $0.03 Per Share


© 2006-2018 Ticker Report. Google+.